黑色素瘤基因组风险管理研究随机对照试验:统计分析计划
本文发布黑色素瘤基因组风险管理随机对照试验的预先设定统计分析计划(SAP),该试验旨在评估提供个体黑色素瘤基因组风险信息对减少紫外线暴露的效果,主要结局为12个月时客观测量的每日总标准红斑剂量。SAP在招募结束后、随访完成前获批,涵盖主要分析及亚组和敏感性分析,健康经济结局另行分析。
要点
- SAP在数据库锁定和分析开始前发布,以避免分析偏倚。
- 主要结局为12个月时客观测量的每日总标准红斑剂量。
- 健康经济结局不纳入本计划,将另行分析。
核心结论
- 该SAP遵循最佳实践,有助于透明报告,并将用于最终数据分析以确保内部效度并最小化分析偏倚。
研究设计与样本
- 随机对照试验,在一般人群中按传统风险组(低或高表型风险)分层,评估提供个体黑色素瘤基因组风险信息对减少紫外线暴露的效果。
关键数值与推荐
- 主要结局为12个月时客观测量的每日总标准红斑剂量。
- 次要结局包括特定时间段的紫外线暴露、自我报告的防晒和皮肤检查行为、心理社会结局及在人群层面提供基因组检测的伦理考量。
- 将进行试验内和模型化经济评估,从澳大利亚卫生系统视角评估干预的成本效果。
局限性
- 健康经济结局未纳入本SAP,将另行分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Melanoma Genomics Managing Your Risk Study is a randomised controlled trial that aims to evaluate the efficacy of providing information on personal genomic risk of melanoma in reducing ultraviolet radiation (UV) exposure, stratified by traditional risk group (low or high phenotypic risk) in the general population. The primary outcome is objectively measured total daily Standard Erythemal Doses at 12 months. Secondary outcomes include UV exposure at specific time periods, self-reported sun protection and skin-examination behaviours, psychosocial outcomes, and ethical considerations surrounding offering genomic testing at a population level. A within-trial and modelled economic evaluation will be undertaken from an Australian health system perspective to assess the cost-effectiveness of the intervention. OBJECTIVE: To publish the pre-determined statistical analysis plan (SAP) before database lock and the start of analysis. METHODS: This SAP describes the data synthesis, analysis principles and statistical procedures for analysing the outcomes from this trial. The SAP was approved after closure of recruitment and before completion of patient follow-up. It outlines the planned primary analyses and a range of subgroup and sensitivity analyses. Health economic outcomes are not included in this plan but will be analysed separately. The SAP will be adhered to for the final data analysis of this trial to avoid potential analysis bias that may arise from knowledge of the outcome data. RESULTS: This SAP is consistent with best practice and should enable transparent reporting. CONCLUSION: This SAP has been developed for the Melanoma Genomics Managing Your Risk Study and will be followed to ensure high-quality standards of internal validity and to minimise analysis bias. TRIAL REGISTRATION: Prospectively registered with the Australian New Zealand Clinical Trials Registry, ID: ACTR N12617000691347 . Registered on 15 May 2017.
引用
- Lo SN, Smit AK, Espinoza D, et al. The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan. Trials. 2020. PMID: 32605576. doi:10.1186/s13063-020-04351-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。